{"success":true,"data":{"pressRelease":{"id":"167427","rtpr_id":"nGNX6X0R90-20261013","ticker":"MGX","exchange":"NASDAQ","all_tickers":["MGX"],"title":"Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference","author":"Globe Newswire","published_at":"2026-10-13T12:00:00.830Z","article_body":"EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics,\nInc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company\ncapitalizing on its proprietary technologies to create curative genetic\nmedicines for patients, today announced that Jian Irish, Ph.D., M.B.A.,\nPresident and Chief Executive Officer of the Company, will participate in a\npanel discussion titled “Genome Editing: Next-Wave Platforms Beyond CRISPR\n1.0” at the Chardan 10th Annual Healthcare Conference on Tuesday, October\n20, 2026, at 10:30 a.m. ET, being held in New York, NY.\n\nA live webcast of the event will be made available on the “News & Events”\npage in the Investors section of the Company’s website at\nhttps://ir.metagenomi.co/news-events/events.\n\nAbout Metagenomi Therapeutics\n\nMetagenomi Therapeutics, Inc. is an in vivo genome editing company\ncapitalizing on its proprietary technologies to create curative genetic\nmedicines for patients. The Company was founded on the science of\nmetagenomics, the study of genetic materials recovered from the natural\nenvironment, to discover and develop a suite of novel CRISPR gene-editing\ntools potentially capable of correcting any type of genetic mutation found\nanywhere in the human genome. The Company focuses on high value programs in\ndisease indications with well-understood biology and clearly defined clinical\ndevelopment and regulatory pathways. Going forward, the Company intends to\ncontinue to expand its pipeline by leveraging its proprietary genetic editing\ncapabilities in site specific deletion, insertion and correction.\n\nMGX-001, the Company’s lead, wholly-owned development program in hemophilia\nA, has demonstrated a preclinical profile with best-in-class treatment\npotential, including targeted genome editing and durable gene expression in a\none-time treatment. MGX-001 is designed to provide curative, life-long\nprotection from bleeding events and joint damage in adults and children,\npotentially enabling a new standard of care for the treatment of hemophilia A.\nThe Company is also currently pursuing indications leveraging the MGX-001\nsite-specific genome integration system and partnered assets targeting\ncardiometabolic diseases. For more information, please visit\nhttps://metagenomi.co/.\n\nInvestor Contact:\nBrian Ritchie\nLifeSci Advisors\nbritchie@lifesciadvisors.com\n\nMedia Contact:\nMichael Fitzhugh\nLifeSci Communications\nmfitzhugh@lifescicomms.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7680f6bf-0803-4567-93bd-b52fc13a7887)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6X0R90-20261013","title":"Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference","author":"Globe Newswire","ticker":"MGX","created":"2026-10-13T12:00:00.830Z","tickers":["MGX"],"exchange":"NASDAQ","article_body":"EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics,\nInc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company\ncapitalizing on its proprietary technologies to create curative genetic\nmedicines for patients, today announced that Jian Irish, Ph.D., M.B.A.,\nPresident and Chief Executive Officer of the Company, will participate in a\npanel discussion titled “Genome Editing: Next-Wave Platforms Beyond CRISPR\n1.0” at the Chardan 10th Annual Healthcare Conference on Tuesday, October\n20, 2026, at 10:30 a.m. ET, being held in New York, NY.\n\nA live webcast of the event will be made available on the “News & Events”\npage in the Investors section of the Company’s website at\nhttps://ir.metagenomi.co/news-events/events.\n\nAbout Metagenomi Therapeutics\n\nMetagenomi Therapeutics, Inc. is an in vivo genome editing company\ncapitalizing on its proprietary technologies to create curative genetic\nmedicines for patients. The Company was founded on the science of\nmetagenomics, the study of genetic materials recovered from the natural\nenvironment, to discover and develop a suite of novel CRISPR gene-editing\ntools potentially capable of correcting any type of genetic mutation found\nanywhere in the human genome. The Company focuses on high value programs in\ndisease indications with well-understood biology and clearly defined clinical\ndevelopment and regulatory pathways. Going forward, the Company intends to\ncontinue to expand its pipeline by leveraging its proprietary genetic editing\ncapabilities in site specific deletion, insertion and correction.\n\nMGX-001, the Company’s lead, wholly-owned development program in hemophilia\nA, has demonstrated a preclinical profile with best-in-class treatment\npotential, including targeted genome editing and durable gene expression in a\none-time treatment. MGX-001 is designed to provide curative, life-long\nprotection from bleeding events and joint damage in adults and children,\npotentially enabling a new standard of care for the treatment of hemophilia A.\nThe Company is also currently pursuing indications leveraging the MGX-001\nsite-specific genome integration system and partnered assets targeting\ncardiometabolic diseases. For more information, please visit\nhttps://metagenomi.co/.\n\nInvestor Contact:\nBrian Ritchie\nLifeSci Advisors\nbritchie@lifesciadvisors.com\n\nMedia Contact:\nMichael Fitzhugh\nLifeSci Communications\nmfitzhugh@lifescicomms.com \n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7680f6bf-0803-4567-93bd-b52fc13a7887)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T12:00:01.021482806Z","server_sent_at_ms":1791892801021},"received_at":"2026-10-13T12:00:01.072Z","source_url":null},"analysis":{"id":"155724","press_release_id":"167427","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Metagenomi Therapeutics (Nasdaq: MGX) announced that CEO Jian Irish will participate in a genome editing panel at the Chardan 10th Annual Healthcare Conference on October 20, 2026, at 10:30 a.m. ET in New York.\n\nA live webcast will be available on the company's investor relations website.\n\nThe release contains no new clinical or financial data; it restates the company's pipeline positioning, including lead hemophilia A program MGX-001.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance notice — no new data; suppress unless panel commentary becomes newsworthy."},"keyFigures":{},"namedEntities":{"people":[{"name":"Jian Irish, Ph.D., M.B.A.","role":"President and CEO"}],"products":["MGX-001"],"companies":[{"name":"Metagenomi Therapeutics, Inc.","ticker":"MGX"},{"name":"Chardan","relationship":"conference host"},{"name":"LifeSci Advisors","relationship":"investor relations contact"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of CEO participation in a healthcare conference panel with a webcast. No new financial, clinical, or regulatory information disclosed."},"tickerRelevance":{"others":[],"primary":"MGX"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"hasNewData":false,"tickerTier":"small-cap-biotech","eventGravity":"conference-participation-notice"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Metagenomi Therapeutics (Nasdaq: MGX) announced that CEO Jian Irish will participate in a genome editing panel at the Chardan 10th Annual Healthcare Conference on October 20, 2026, at 10:30 a.m. ET in New York.\n\nA live webcast will be available on the company's investor relations website.\n\nThe release contains no new clinical or financial data; it restates the company's pipeline positioning, including lead hemophilia A program MGX-001.","key_figures":{},"named_entities":{"people":[{"name":"Jian Irish, Ph.D., M.B.A.","role":"President and CEO"}],"products":["MGX-001"],"companies":[{"name":"Metagenomi Therapeutics, Inc.","ticker":"MGX"},{"name":"Chardan","relationship":"conference host"},{"name":"LifeSci Advisors","relationship":"investor relations contact"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:00:11.805Z","global_importance":5,"audience_relevance":10,"importance_components":{"hasNewData":false,"tickerTier":"small-cap-biotech","eventGravity":"conference-participation-notice"}},"durationMs":4085,"modelName":"glm-5.3-flashx"}}